Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide - AstraZeneca

Drug Profile

Exenatide - AstraZeneca

Alternative Names: AC 2993; AC002993; AC2993A; Byetta; Exendin 4; LY2148568

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Radboud University; Regional and University Hospital of Besancon
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II/III Metabolic disorders; Type 1 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 28 Jun 2019 AstraZeneca plans a phase I trial in Type-2 diabetes mellitus in China (NCT04001231)
  • 23 May 2019 Astrazeneca suspends patient enrolment in a phase III trial in Type 2 diabetes mellitus (Adjunctive treatment, In adolescents) in USA, Mexico, South Korea, India, South Africa, Russia, Philippines and Brazil as the IP will expire in September 2019, and there are currently delays to new IP resupply (SC) (NCT00658021)
  • 06 Aug 2018 Eli Lilly completes the phase II/III EXEPUMP trial for Type-2 diabetes mellitus (Adjunctive treatment) in France (SC) (NCT01140893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top